EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Microneedling for the Treatment of Acne Scars: A Scoping Review of Therapeutic Protocols, Combination Therapies, and Current Evidence

Luca Castellano, Angela Capponi, Pier Paolo Rovatti, Elisa Campomagnani, Ilaria Maccari

Journal of Cosmetic Dermatology · 2026-11 · 25 (11)

DOI: 10.1111/jocd.71285 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background/Objectives Atrophic acne scarring is a complex condition with no definitive single treatment. Microneedling (MN) is a safe alternative to ablative procedures because it preserves the epidermis, minimizing the risk of post‐inflammatory hyperpigmentation. This scoping review maps the available literature on the technical parameters, multimodal protocols, and knowledge gaps associated with mechanical MN for acne scar revision. Methods Following JBI and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses extension for Scoping Reviews (PRISMA‐ScR) guidelines, a systematic search was conducted across PubMed and Scopus for English‐language articles published over the last decade. Both primary clinical research and secondary evidence syntheses evaluating manual and motorized mechanical MN were included. Results A total of 85 studies met the inclusion criteria. Extracted data reveal a dichotomy between manual dermarollers and motorized pens, with penetration depths ranging from 0.5 to 3.0 mm. Because MN monotherapy shows limited efficacy for complex lesions, current protocols have shifted clearly toward multimodal regimens. MN is frequently combined with surgical subcision, chemical peels, and transdermal agents. Platelet‐Rich Plasma (PRP) is the most widely utilized adjunct, while topical human insulin is emerging as a promising alternative. Conclusions The mapped evidence supports MN as a safe bridging intervention for multimodal scar management. However, this review identifies a critical methodological gap: the pervasive reliance on truncated follow‐up periods (1 to 3 months). This abbreviated timeline predominantly captures transient inflammatory edema rather than definitive neocollagenesis, risking an overestimation of long‐term efficacy. Future clinical trials must implement a minimum follow‐up of 6 to 12 months alongside objective biometric assessments.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →